Evidence map›Paper›PMID 41983134›Full record

ReviewFrontiers in immunology2026

Mitochondrial dysfunction in immune cells during the perioperative period: mechanisms, emerging therapeutic strategies, and implications for multi-organ protection.

Ziyu Wang, Lu Wang, Maolin Ji, Jie Lou, Yuchuan Yuan, Yuanxu Cui, Gang Xiang, Xing Zhou

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ziyu Wang *School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
Lu Wang *School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
Maolin Ji *School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
Jie LouSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
Yuchuan YuanNorthwest University, Xi'an, China.
Yuanxu CuiYunnan Key Laboratory of Stem Cell and Regenerative Medicine, Rehabilitation School, Kunming Medical University, Kunming, China.
Gang XiangSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
Xing ZhouYunnan Key Laboratory of Stem Cell and Regenerative Medicine, Rehabilitation School, Kunming Medical University, Kunming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial health is increasingly recognized as a critical determinant of immune competence during the perioperative period. Surgical interventions impose unique metabolic and inflammatory stresses-such as ischemia-reperfusion injury, anesthetic exposure, and systemic inflammatory responses-that impair immune cell bioenergetics and redox balance. Dysfunctional mitochondria in neutrophils, macrophages, and T lymphocytes alter cytokine production, phagocytic activity, and antigen presentation, tipping the balance toward excessive inflammation or postoperative immunosuppression, thereby exacerbating organ injury. This review integrates current knowledge of the mechanisms linking perioperative mitochondrial dysfunction to immune dysregulation, and systematically evaluates emerging therapeutic strategies, including mitochondrial-targeted antioxidants, permeability transition pore inhibitors, metabolic reprogramming agents, mitochondrial transplantation, and gene-based interventions. By bridging experimental evidence with translational and early clinical studies in cardiac, neurological, hepatic, and renal surgeries, we argue that precise modulation of immune cell mitochondrial function represents a promising and underexplored frontier for comprehensive perioperative organ protection.

Indexed as

MitochondriaPerioperative PeriodAnimalsHumansMacrophagesimmune cellsimmunomodulationmitochondrial dysfunctionorgan protectionperioperative period

Identifiers

PMID41983134
PMCPMC13070836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.